STF-31

Catalog No.S7931 Batch:S793102

Print

Technical Data

Formula

C23H25N3O3S
Molecular Weight 423.53 CAS No. 724741-75-7
Solubility (25°C)* In vitro DMSO 85 mg/mL (200.69 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description STF-31 is a selective glucose transporter GLUT1 inhibitor.
Targets
GLUT1 [1]
In vitro STF-31 selectively kills RCCs by specifically targeting glucose uptake through GLUT1. STF-31 significantly inhibits lactate production and extracellular acidification in VHL-deficient cells by about 60%, and decreases glycolysis by decreasing glucose transport. [1] In NAPRT1-expressing cells, STF-31 shows cytotoxicity by inhibiting the enzymatic activity of NAMPT. [2] STF-31 is toxic to hPSCs and efficient for selective elimination of hPSCs from mixed cultures. [3]
In vivo In mice with VHL-deficient RCC xenografts, a more soluble analog of STF-31 (11.6 mg/kg, i.p.) markedly delays tumor growth. [1]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    RCC4/VHL and RCC4 cells

  • Concentrations

    --

  • Incubation Time

    4 d

  • Method

    For XTT assays, five thousand cells are plated in 96-well plates. The next day, vehicle (DMSO) or drug is added by serial dilution. Four days later, media are aspirated, XTT solution (0.3 mg/ml of XTT, 2.65 μg/ml N-methyl dibenxopyrazine methyl sulfate in phenol red-free media) is added, and the plates are incubated at 37°C for 1-2 hours. Metabolism of XTT is quantified by measuring the absorbance at 450 nm. IC50s are calculated using linear interpolation. All conditions are measured in triplicate and each experiment is done in duplicate or triplicate.
Animal Study:

[1]
  • Animal Models

    Mice with VHL-deficient RCC xenografts

  • Dosages

    11.6 mg/kg

  • Administration

    i.p.

Customer Product Validation

Data from [Data independently produced by , , J Virol, 2017, 91(6)]

Selleck's STF-31 has been cited by 12 publications

Disruption of the IL-33-ST2-AKT signaling axis impairs neurodevelopment by inhibiting microglial metabolic adaptation and phagocytic function [ Immunity, 2022, 55(1):159-173.e9] PubMed: 34982959
Core-shell nanosystems designed for effective oral delivery of polypeptide drugs [ J Control Release, 2022, 352:540-555] PubMed: 36323363
Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis [ Mol Oncol, 2022, 16(15):2861-2880] PubMed: 35665592
A positive feedback circuit comprising p21 and HIF-1α aggravates hypoxia-induced radioresistance of glioblastoma by promoting Glut1/LDHA-mediated glycolysis [ FASEB J, 2022, 36(3):e22229] PubMed: 35199870
Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway. [ Cell Metab, 2020, 31(3):564-579] PubMed: 32130883
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. [ Theranostics, 2020, 6;10(12):5259-5275] PubMed: 32373211
Improved Immunoregulation of Ultra-Low-Dose Silver Nanoparticle-Loaded TiO2 Nanotubes via M2 Macrophage Polarization by Regulating GLUT1 and Autophagy. [ Int J Nanomedicine, 2020, 24;15:2011-2026] PubMed: 32273699
Activating Transcription Factor 3 Coordinates Differentiation of Cardiac and Hematopoietic Progenitors by Regulating Glucose Metabolism [ Sci Adv, 2020, 6;6(19):eaay9466] PubMed: 32494702
mTORC2-mediated PDHE1α nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma. [ Oncogene, 2019, 38(24):4669-4684] PubMed: 30745576
Monosaccharide Analogues of Anticancer Peptide R-Lycosin-I: Role of Monosaccharide Conjugation in Complexation and the Potential of Lung Cancer Targeting and Therapy. [ J Med Chem, 2019, 62(17):7857-7873] PubMed: 31276399

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.